helioxanthin has been researched along with dinoprostone in 1 studies
| Studies (helioxanthin) | Trials (helioxanthin) | Recent Studies (post-2010) (helioxanthin) | Studies (dinoprostone) | Trials (dinoprostone) | Recent Studies (post-2010) (dinoprostone) |
|---|---|---|---|---|---|
| 24 | 0 | 10 | 29,105 | 1,346 | 6,357 |
| Protein | Taxonomy | helioxanthin (IC50) | dinoprostone (IC50) |
|---|---|---|---|
| Prostaglandin E2 receptor EP1 subtype | Homo sapiens (human) | 0.0155 | |
| Prostaglandin E2 receptor EP4 subtype | Homo sapiens (human) | 0.0031 | |
| Prostaglandin E2 receptor EP4 subtype | Rattus norvegicus (Norway rat) | 0.0021 | |
| Prostaglandin E2 receptor EP3 subtype | Homo sapiens (human) | 0.002 | |
| Prostaglandin E2 receptor EP2 subtype | Homo sapiens (human) | 0.0087 | |
| Prostacyclin receptor | Homo sapiens (human) | 0.26 | |
| Prostaglandin E2 receptor EP2 subtype | Rattus norvegicus (Norway rat) | 0.0052 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bau, DT; Hsieh, YL; Hsien, HH; Hsu, HH; Huang, CY; Kuo, WW; Lin, YM; Tu, CC; Velmurugan, BK; Viswanadha, VP | 1 |
1 other study(ies) available for helioxanthin and dinoprostone
| Article | Year |
|---|---|
Helioxanthin suppresses the cross talk of COX-2/PGE2 and EGFR/ERK pathway to inhibit Arecoline-induced Oral Cancer Cell (T28) proliferation and blocks tumor growth in xenografted nude mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Arecoline; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Cyclooxygenase 2; Dinoprostone; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; G2 Phase Cell Cycle Checkpoints; Heterografts; Lignans; Male; MAP Kinase Signaling System; Mice, Nude; Mouth Neoplasms; Signal Transduction; Transcription Factor AP-1 | 2016 |